Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Trial Identifier:	D419MC00006
Sponsor:	AstraZeneca
NCTID::	NCT05826366
Start Date:	June 2023
Primary Completion Date:	November 2025
Study Completion Date:	November 2025
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan
Japan	Hokkaido, Japan

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company